Literature DB >> 9922302

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.

D Gillen1, A A Wirz, J E Ardill, K E McColl.   

Abstract

BACKGROUND & AIMS: There have been conflicting reports regarding acid secretion after treatment with omeprazole. This study examined acid secretion after treatment with omeprazole and its relation to Helicobacter pylori status and on-treatment gastric function.
METHODS: Twelve H. pylori-negative and 9 H. pylori-positive subjects were examined before, on, and at day 15 after an 8-week course of 40 mg/day omeprazole. On each occasion, plasma gastrin, intragastric pH, and acid output were measured basally and in response to increasing doses of gastrin 17.
RESULTS: In the H. pylori-negative subjects at day 15 after omeprazole treatment, basal acid output was 82% higher (P < 0.007) and maximal acid output 28% higher (P < 0.003) than before omeprazole. The degree of increase in maximal acid output was related to both on-treatment pH and on-treatment fasting gastrin levels, being 48.0% in subjects with an on-treatment pH of >4 vs. 21. 0% in those with a pH of <4 (P < 0.02) and 49.2% in subjects with an on-treatment gastrin of >25 ng. L-1 vs. 19.8% in those with a fasting gastrin of <25 ng. L-1 (P < 0.006). At day 15 after omeprazole treatment, the H. pylori-positive subjects showed a heterogeneous response with some having increased acid output and others persisting suppression.
CONCLUSIONS: Rebound acid hypersecretion occurs in H. pylori-negative subjects after omeprazole treatment. Its severity is related to the degree of elevation of pH on treatment. Persisting suppression of acid secretion masks the phenomenon in H. pylori-positive subjects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9922302     DOI: 10.1016/s0016-5085(99)70118-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

1.  Mechanisms involved in Helicobacter pylori induced duodenal ulcer disease:an overview.

Authors:  Lars Olbe; Lars Fandriks; Annika Hamlet; Ann-Mari Svennerholm; Ann-Catrin Thoreson
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Helicobacter pylori infection and long term proton pump inhibitor therapy.

Authors:  K E L McColl
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

3.  Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Protagonist.

Authors:  L Lundell
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 4.  Eradication of Helicobacter pylori: a clinical update.

Authors:  Marco Romano; Antonio Cuomo
Journal:  MedGenMed       Date:  2004-02-17

5.  The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.

Authors:  T D Barrett; G Lagaud; P Wagaman; J M Freedman; W Yan; L Andries; M C Rizzolio; M F Morton; N P Shankley
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

Review 7.  Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion.

Authors:  Guanglin Cui; Helge L Waldum
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

8.  A close look at acid reflux drugs points to possible risks.

Authors:  Alisa Opar
Journal:  Nat Med       Date:  2009-07       Impact factor: 53.440

9.  GERD: increased gastric acid secretion as a possible cause of GERD.

Authors:  Jerry D Gardner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03       Impact factor: 46.802

Review 10.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.